Live
FierceBiotechAI could help spot heart disease in routine breast mammogram screeningsBioPharma DiveVertex kidney disease drug hits mark in late-stage studyThermo FisherThermo Fisher looks to shake up Bay Area biotech with 10-foot microscope - The Business JournalsIlluminaSPT-Illumina partnership ‘delivers core facilities to decentralised labs’ - Cambridge IndependentBioPharma DiveBristol Myers claims success in study of another next-gen blood cancer drugLonza NewsBRIEF—Lonza and Genetix Biotherapeutics extend deal - The Pharma LetterEndpoints NewsIpsen pulls cancer drug Tazverik from market over safety risksEndpoints NewsWhat Prasad's exit means for the FDA moving forwardAgilentAgilent Technologies to acquire Biocare Medical in $950m deal - Yahoo FinanceBioPharma DiveRoche’s prized breast cancer pill fails closely watched studyFierceBiotechTenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater ChinaFierceBiotechFDA greenlights backup anti-choking suction device
Endpoints News Jan 21, 2026

Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s

Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s

Original
Body unavailable. Use the original source.

Directory

59 All